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8 Current National Institute for Health and Care Excellence (NICE) guidelines for psychosis 
10 recommend psychological therapy with or without family 
11 
12 intervention for individuals at-risk of developing psychosis. 
13 NICE guidelines have a 
15 
specific research recommendation to investigate the clinical and cost effectiveness of 
16 
17 combined individual and family intervention. We report the rationale, design and 
18 
19 baseline characteristics of a feasibility study investigating combined Individual 






27 The IFCBT study was a single blind, pilot randomised controlled trial (RCT) to compare a 
29 combined individual and family Cognitive Behavioural Therapy (CBT) intervention to 
30 
31 treatment as usual. Participants were assessed using the Comprehensive Assessment of the 
32 At-risk Mental State (CAARMS) and randomly allocated to either therapy or enhanced 
34 treatment as usual (ETAU). All participants were followed up at six and twelve months. 
35 
36 Primary feasibility outcomes were recruitment and retention of participants. Secondary 
37 
38 outcomes included transition to psychosis and assessment of mood, anxiety and the 






46 We report data showing entry into the study from initial enquiry to randomisation. We report 
48 the characteristics of the recruited sample of individuals (n=70) and family members (n=70) 
49 





55 The study recruited to 92% of target demonstrating it is feasible to identify and recruit 
56 
57 participants. Our study aimed to add to the current evidence base regarding the utility of 
58 family interventions for people at-risk of psychosis. 
60 
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10 Over the last decade there has been increasing interest in the ability to identify and 
11 
12 intervene early in the onset of psychosis (Fusar-Poli et al., 2013). Researchers have 
13 validated operational criteria to identify those with an ‘At-risk Mental State’ 
15 (ARMS) for psychosis, allowing early identification of individuals at high risk of 
16 
17 developing Schizophrenia or related psychotic disorders. Following successful 
18 
19 identification of people meeting criteria for ARMS, researchers and clinicians are now 
20 focusing on prevention and intervention strategies. The personal, social and economic 
22 burden associated with psychosis has been a key driver for development of effective 
23 
24 interventions to prevent transition to psychosis. 
25 
26 




31 A systematic review which examined 28 studies, indicated transition rates of 
32 children and adolescents from ARMS to psychosis were 40% at 6 months, between 17- 
34 20% at 1 year, and between 7-21% at 2 years (Tor et al., 2017). These rates are 
35 
36 consistent with an earlier meta-analysis of transition outcomes, which found individuals 
37 
38 to be at very high risk of developing psychosis within the first 3 years of clinical 
39 presentation (Fusar-Poli et al., 2012). In the long-term, the ARMS is significantly 
40 
41 associated with increased risk of developing psychosis, but the accuracy is modest, 
42 
43 demonstrating the Brief Limited Intermittent Psychotic Symptoms (BLIPS) subgroup at 
44 a higher risk compared to the Attenuated Psychotic Symptom (APS) subgroup 
46 (p<0.001) (Fusar-Poli et al., 2017). 
47 
48 
49 Several randomised controlled trials (RCTs) of interventions for individuals who meet 
50 criteria for ARMS have been conducted. Interventions included non-pharmacological 
52 interventions such as CBT (Morrison et al., 2004; Morrison et al., 2012; Stain et al., 
53 
54 2016; Addington et al., 2011), family therapy (Miklowitz et al., 2014) and cognitive 
55 
56 remediation (Hooker et al., 2014; Urben et al., 2012); pharmacological interventions 
57 using antipsychotics (Bechdolf et al., 2017; McGorry et al., 2013; McGlashan et al., 
59 
60 











3 2006; Woods et al., 2003) and experimental pharmacotherapies such as omega-3 fatty 
4 





10 The National Institute for Health and Care Excellence (NICE, 2014) guidelines 
11 
12 (guideline CG178) development group, found moderate evidence for CBT, concluding 
13 that further research in complex psychological interventions is required. This was 
15 consistent with findings published in NICE guidelines (2014) for psychosis and 
16 
17 schizophrenia that suggests antipsychotic medication should not be used as a first line 
18 
19 treatment of ARMS but supported the use of psychological interventions. They also 
20 made a specific research recommendation for the conduct of a trial of combined 





27 A further meta-analysis supported the findings of the NICE guideline group (van der 
28 
29 Gaag et al., 2013). A 2014 meta-analysis focusing specifically on CBT found that the 
30 
31 relative risk of developing psychosis was reduced by more than 50% for those receiving 
32 CBT at every time point and concluded that CBT-informed treatment is associated with a 
34 reduced risk of transition to psychosis at 6, 12 and 18–24 months, and reduced symptoms 
35 





41 Results from previous treatment studies have been invariably mixed and often 
42 
43 conflicting. The evidence for a specific intervention superiority in psychosis prevention 
44 remains inconclusive (Davies et al., 2018). However earlier meta-analysis that compare 
46 all trial interventions (both psychosocial and pharmacological) with needs-based 
47 
48 interventions indicate that in group-level analysis of most ARMS individuals improve in 
49 
50 their symptoms and functioning over time, with transition rated reduced and delayed 



















          Study rationale and aims 
 
                                         To our knowledge, there have been two published studies 
 
 
 examining the potential for family interventions with this group to reduce the rate of 
 
 transition to psychosis. This is despite the evidence base for family interventions for 
  psychosis, which show an ability to reduce relapse rates and provide better prognosis 
 (Pharoah, Mari, Rathbone, & Wong, 2010; Pitschel-Walz, 
 
49 Leucht, Bäuml, Kissling, & Engel, 2001). In addition, a recent systematic review looking 
50 at the family environment in ARMS found higher criticism and hostility linked to poorer 
 
functioning and worse symptoms in families of ARMS, with similar rates of high 
 
 expressed emotion compared to First Episode Psychosis (Izon et al., 2018). Miklowitz et 
 
56 al. (2014) found 6 of 102 participants transitioned to psychosis, with an overall risk of 
57 6%. None of the 6 participants who converted were taking antipsychotic medications at 
58  entry. There were fewer transitions in the FI group (2% compared to 11%) with the FI 
 














3 participant transitioning within 30 days of randomisation. The FI was associated with 
4 
5 greater improvements in attenuated symptoms over 6 months relative to control. Key 
6 
7 components included psychoeducation and development of a prevention plan with the 
8 service-user and family. Sessions focused on improving communication and focusing on 
10 enhancing problem solving skills. A further study (Landa et al, 2016) investigated 
11 
12 different group-and-family based CBT interventions, finding statistically significant 
13 decreases in attenuated psychotic symptoms, negative symptoms, depression and 
15 
improvements in functioning. Family members showed significant improvements in use 
16 
17 of CBT skills, enhanced communication with their offspring, and greater confidence in 
18 
19 their ability to help. However, this was a small (N=6), open, uncontrolled study and 














37 Additional family studies found integrated treatment of social skills training and multi- 
38 family group psychoeducation significantly reduced risk of transition compared to 
40 standard care in ARMS individuals with schizotypal disorder (Nordentoft et al, 2006). 
41 
42 One pilot study separated individuals at the highest risk of psychosis transition to a 
43 
44 family-aided assertive community treatment, whilst those with lower risk were assigned 
45 to community care (McFarlane et al, 2015). Although there were no differences in 
47 transition, the family treatment had some benefits over community care. There is limited 
48 
49 literature of family RCTs with suggestions for treatment strategies combining family and 
50 
51 individual CBT (Stafford et al., 2013; Miklowitz et al., 2014; NICE, 2014). 
52 
53 The current study aimed to investigate the feasibility of a combined Individual and 
54 
55 Family Cognitive Behavioural Therapy (IFCBT) for people considered to be at- 
56 
57 risk of developing psychosis. Our primary outcome was to recruit and consent to 
58 participate in a randomised trial, adhere to the intervention, retain participants across 
60 both arms through assessment at follow-ups and gather data to inform outcome 














3 parameter estimates. From this, we will be able to assess the acceptability of the 
4 
5 intervention to service users and their key family member/carer. Furthermore, the trial 
6 
7 will provide initial indications of the impact of a combined approach of individual CBT 
8 and family intervention on transition rates to inform the primary outcomes for a future 




14 The main study was a single (rater) blind randomised feasibility study with two 
16 conditions; Individual and Family CBT (IFCBT) plus enhanced treatment as usual 
17 
18 (ETAU) vs. ETAU alone in people considered to be at high- risk of developing 
19 psychosis. The trial randomly allocated participants who met criteria to a 6-month 
21 
package of either condition, using a secure telephone randomisation service. 
22 
23 Assessments were conducted by research assistants, who were blind and independent to 
24 
25 treatment group. Participants were made aware to conceal their allocation from the 
26 research assistants when they were in correspondence and during follow-up assessment. 
28 All allocation data was inaccessible to research assistants, with separate offices utilised 
29 
30 to retain the blind. Assessments were conducted at baseline, post treatment (6 months) 
31 
32 and follow-up (12 months) with both the individual and their nominated family 
33 member/carer. There was also a nested qualitative study to identify key themes 
35 associated with the acceptability of IFCBT in individuals at high risk of psychosis and 
36 
37 experiences of being involved in the trial. Additionally, family members/carers of 




43 The study was approved by the North West - Greater Manchester East Ethics Committee 









54 A sample size of 60 is considered adequate for obtaining reliable sample size  
55 
56 estimates, which will facilitate the main aims of a feasibility study (Sim & Lewis, 
57 2012). Based on requiring 60 participants across conditions, a target recruitment of 76 
59 (38 per condition) over the recruitment period would allow a dropout rate of 20%. 
60 













3 Formal sample size calculations were not appropriate for a pilot study aimed at 
4 
5 establishing feasibility and statistical significance of any findings will not be the primary 
6 
7 focus of the analysis. The sample will also include a family member, carer or loved one 
8 as nominated by each participant (we will use the term family/carer for this throughout 
10 this paper). 
11 
12 
13 Recruitment took place across 2 mental health trusts in North West England (Greater 
14 Manchester Mental Health NHS foundation Trust and Pennine Care NHS Trust) 
16 primarily via Early Intervention in Psychosis teams. Participants were also able to self- 
17 




22 a) Aged 16-35. 
23 
24 b) Screen positive on the CAARMS for an At-risk Mental State. 
25 
26 c) Be living (or in regular contact) with a family member, carer or loved one. 
27 d) Help seeking. 
28 
29 
30 Exclusion Criteria 
31 
32 a) Receipt of anantipsychotic medication to 
33 treat symptoms of psychosis. 
34 
35 b) Moderate to severe learning disability. 
36 
37 c) Organic impairment. 
38 d) Insufficient fluency in English. 




44 Assessment of eligibility and outcome measures 
45 Trial eligibility was assessed using the Comprehensive Assessment of At-risk 





i) trait vulnerability risk factors, defined by the presence of either a first degree 





ii) state risk factors, defined by the presence of transient psychotic symptoms, 
59 called Brief Limited Intermittent Psychotic Symptoms (BLIPS); 
60 


















According to the CAARMS criteria (Yung et al., 2006), individuals within each 





Full assessments were conducted by assessors blind and independent to treatment group 
15 on three occasions: initial baseline, 6 months post randomisation (post-treatment for the 
16 
17 therapy group) and 12 months post randomisation. Individual participants were 
18 
19 reimbursed £20 for their time at each assessment, family member/carers £10 and both 
20 received £10 for any additional qualitative interviews. All eligibility decisions were 
22 confirmed by a qualified clinician and all assessors were fully trained in the measures 
23 










34 The main objective was to evaluate the feasibility of the trial. Primary feasibility 
35 
36 outcomes were therefore: recruitment and retention of participants in both arms of the 
37 study and adherence to therapy. The primary clinical outcome is transition to psychosis 





Secondary outcome measures for both participant and family member/carer will include 
45 the Time Use Survey, Beck Depression Inventory (BDI) and the Social Interaction 
46 
47 Anxiety Scale (SIAS).  
48 
49  
50 Data on health status will be collected by the EQ-5D and used to estimate the 
52 health-related utility scores of participants. Furthermore, we  assessed 
53 
54 the relationship and individual’s perceptions of their relationship between themselves 
55 
56 and the carer using the Family Questionnaire, Five Minute Speech Sample, Relationship 
57 Structure Questionnaire (ECR-RS) and the Perceived Criticism and Warmth 
59 Questionnaire. Additionally, we assessed carer burden and  
60 














3 additional measures on their carer health (GHQ), and carer needs (BDI, 
4 






11 Following written consent, eligible participants were randomised using Christie's secure 
12 
13 telephone randomisation service. Randomisation (at the individual level) was 
14 independent and concealed, using randomised-permuted blocks of 6-8 and stratified by 
16 age and gender. Allocation was communicated to trial manager (to monitor adherence to 
17 
18 the randomisation algorithm), trial therapist and made known to the participant by letter 
19 from the administrator. Blinding of allocation was maintained for research assistants, 
21 
until all outcome measures for all subjects were collected. Blindness was maintained 
22 
23 using a range of measures (e.g. separate offices for therapist and researchers, protocols 
24 
25 for answering phones, message taking and secretarial support, separate diaries and 
26 security for electronic randomisation information). A dual-purpose 
28 independent Trial Steering Committee (TSC) and Data Monitoring and Ethics 
29 




34 The intervention was a combination of Individual and Family Cognitive Behavioural 
35 
36 Therapy (IFCBT). The individual CBT treatment was based on that used in several 
37 
38 previous treatment studies (French & Morrison, 2004; Morrison et al., 2012; 
39 Morrison et al., 2004). The family component was an additional 4 - 6 sessions of CBT 
41 with key family members such as parents or carers, to compliment the individual work. 
42 
43 Sessions focused on assessment, formulation, problems and goal setting, communication 
44 styles and problem solving. The family intervention followed NICE guidelines by 
46 including the client and taking account of the relationship between the parent and or 
47 
48 carer and the young person. The family/carer component was delivered in tandem with 
49 
50 the individual CBT and delivered by the same therapist to maintain engagement and 
51 consistency of approach. Participants received the intervention as well as enhanced 
53 treatment as usual (ETAU). 
54 
55 
56 Participants who were not allocated to the intervention arm received  
57 (ETAU) alone. Irrespective of their group allocation, all Participants were able 
59 to access or continue with their treatment as usual (which may include care from an 
 
60 















3 Early Intervention Service). Early Intervention Services offer treatment to prevent 
4 
5 psychosis in accordance with current NICE guidelines which state they should “offer 
6 
7 individual cognitive behavioural therapy (CBT) with or without family intervention” and 
8 “offer interventions recommended in NICE guidance for people with any of the anxiety 
10 disorders, depression, emerging personality disorder or substance misuse” (NICE, 2014). 
11 
12 
13 Enhancements to TAU involved monitoring of symptoms via structured interview, which 
14 is associated with the perceived benefits including having a chance to talk at length about 
16 concerns. Participants were also given a crisis card providing contact details for 
17 
18 appropriate local sources of help in psychiatric emergency and offered a full assessment 
19 summary letter. ETAU included liaison with the clinical team, especially around risk 
21 
issues with a clear safety protocol to alert clinicians, should suicidal or dangerous 
22 
23 ideation emerge. The use of ETAU as a control has the advantage of ensuring all trial 
24 
25 participants derive some benefit from the trial, ensuring that it conforms to the highest 




31 The main aims of the feasibility study will be delivered both via the continued monitoring 
32 of descriptive data and the analysis of data at the end of the last follow-up assessment. 
34 This will include reporting data in line with the Consolidated Standards of Reporting Trials 
35 
36 (CONSORT) 2010 Statement, showing attrition rates and loss to follow-up. Analyses of 
37 
38 outcomes will not be focused on statistical significance, but will concentrate on descriptive 
39 statistics and confidence intervals for treatment effects. The primary clinical outcome, 
41 conversion to psychosis, will be examined using a discrete-time survival model. A detailed 
42 







51 Recruitment to the trial finished in August 2018 with a final sample of 70, with 34 
53 individuals allocated to ETAU and 36 allocated to the Individual and Family Cognitive 
54 
55 Behavioural Therapy (IF CBT). The final sample of 70 represented 92% of the original 
56 target sample size of 76. Each individual participant nominated a family member/carer to 
58 
take part, leading to an overall final sample of 140. Initially, participants were able to 
59 
60 nominate multiple family/carers (some nominating up to 3). However, it became 








3 apparent that this number of family/carer participants would not be feasible to follow up 
4 
5 within the study. Therefore, participants were required to choose just one family/carer 
6 





12 Demographic characteristics of the sample can be seen in table 2. Baseline variable 
13 scores including CAARMS subscale scores for participants can be found in table 3. 
15 Table 4 includes baseline variable scores for family member/carer. The initial 
16 
17 CONSORT diagram for entry into the trial is shown in figure 1. The CONSORT 
18 
19 highlights a high proportion of initial enquiries, with only a third referred. This may 
20 reflect Early Intervention of Psychosis services that aim to meet the needs of those at- 
22 risk of developing psychosis, those who have already experienced a first episode of 
23 

































































[insert Table 4: Family member/carer baseline variable scores] 
20 
21 







29 The IF CBT study was a single rater, blind randomised feasibility study comparing individual and 
30 Family CBT (IFCBT) plus enhanced treatment as usual (ETAU), to ETAU alone in people considered to 
31 
32 be at high risk of developing psychosis. This pilot feasibility study was in line with the research 
33 
34 recommendation in the NICE guidelines for psychosis and schizophrenia in children and young 
35 people (NICE., 2014), which states a need to establish the clinical and cost effectiveness of a 
36 
37 combined family intervention with individual CBT for those considered to be at-risk of 
38 
39 developing psychosis. Previous meta-analysis (Davies et a., 2018) suggests conflicting results 
40 regarding the efficacy of many trials and their tested treatments. As discussed, two studies examined 
42 the potential for family interventions for ARMS with reduced rates of transition to psychosis in 
43 
44 comparison to usual care, fewer transitions and greater improvements in attenuated symptoms in 
45 the FI group relative to control (Miklowitz et al., 2014), albeit, despite methodological shortcomings 
47 of one study (Landa et al., 2014). In line with treatment recommendations from NICE 
48 
49 guidelines (2014), the current trial is the first of its kind that compares a combined approach of 
50 
51 individual and family intervention to usual care. This study provides a significant first step in 




57 Our sample was mostly male, young and predominantly White British. This is a similar 
58 sample profile to other ARMS studies (McGorry, 2014; Morrison et al., 2012), 
60 although the lack of ethnic diversity in the sample may limit generalisability of findings to 














3 other ethnic groups. The majority of participants were eligible for the trial due to 
4 
5 experiencing attenuated psychotic symptoms and having moderately to severely impaired 
6 
7 functioning. Again, this is consistent with other trials of the ARMS population. 
8 
9 The study enabled referrals from voluntary sectors, self-referrals as well as NHS sector 
10 
11 organisations, enabling multiple entrances into the trial. Unlike other trials of interventions 
12 
13 for people at-risk of developing psychosis, referrals to the study were predominantly 
14 from Early Detection and Intervention in Psychosis Services. The high number of 
16 referrals received in the trial and those ineligible is likely to reflect the evolving role of Early 
17 
18 Intervention Services to meet the needs of those at-risk of developing psychosis, as 
19 well as those who have already experienced a first episode of psychosis. In terms of 
21 
feasibility of future studies for young people with an at-risk mental state and indeed a 
22 
23 definitive trial of combined family and individual interventions, this evolution of Early 
24 
25 Intervention Services allows researchers to have a direct referral pathway for ARMS 
26 populations from clinical services into research trials, allowing an efficient and effective way 
28 to identify eligible participants and offer them the option of taking part in research. 
29 
30 
31 Interestingly, despite the increased availability of support and intervention from these clinical 
32 services, many young people still opted to take part in the research trial. Only 13% declined 
34 to take part after being referred, with reasons varying from not help seeking, not being 
35 
36 interested in the research or personal reasons for not wanting to be involved. An additional 
37 
38 9% decided not to take part due to not wanting family member/carer involved in their care or 
39 not having anyone they could nominate to be involved. The majority of young people chose 
41 to nominate their parent as the family/carer in the study, although interestingly, a quarter of 
42 
43 participants chose to nominate a partner to take part in the intervention, which may suggest a 
44 need for a partner/spouse specific intervention. In comparison to previous family studies, 
46 other relatives and friends could be involved, who were deemed to have a particular 
47 
48 importance to the individual. This may complicate the specific family intervention and be 
49 
50 difficult to compare between individuals and groups, however it may be more reflective of 
51 clinical need of individuals who wish significant  




57 There were no refusals to be randomised following assessment of eligibility. This low rate of 
58 declines/refusals suggests the study and the intervention are highly acceptable to this group, 
60 and therefore recruitment to a definitive trial would be feasible. 











5 The sample presented with high levels of comorbid emotional disorders such as moderate to 
6 
7 severe depression and high levels of social anxiety. This is highly consistent with the existing 
8 literature and sample characteristics from other trials with the ARMS population (Fusar-Poli, 
10 Nelson, Valmaggia, Yung, & McGuire, 2014) . CAARMS scores highlighted high levels of 
11 
12 distress in relation to symptoms, particularly on the non-bizarre ideas subscale. In addition to 
13 high levels of comorbidity and distress for the individuals taking part in the study, some 
15 
nominated family members/carers also presented with moderate depression (BDI score 20- 
16 
17 28), anxiety and physical health problems. 
18 
19 
Data collection was complete in June 2019 and we will report feasibility and 
21 
acceptability via retention rates, completion of the intervention, safety and qualitative 
22 
23 feedback as outlined in this paper and our statistical analysis plan following completion of 
24 
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38 Abbreviations: CAARMS (Comprehensive Assessment of At Risk Mental States); SOFAS 
40 (Social and Occupational Functioning Assessment Scale); EQ-5D (Health Questionnaire); 
41 GHQ (General Health Questionnaire); BDI (Beck Depression Inventory); SIAS (Social 
42 Interaction Anxiety Scale); PSWQ (Penn State Worry Questionnaire); FMSS (Five Minute 
43 
44 Speech Sample); FQ (Family Questionnaire); ECR-RS (Relationship Structures); PCPW 
45 (Perceived Criticism and Warmth Questionnaire). 
46 
Measure Baseline 6 months 12 month 













EQ-5D ✓ ✓ ✓ ✓ ✓ ✓ 









BDI ✓ ✓ ✓ ✓ ✓ ✓ 
SIAS ✓ ✓ ✓ ✓ ✓ ✓ 
PSWQ ✓ ✓ ✓ ✓ ✓ ✓ 
FMSS  ✓  ✓  ✓ 
FQ ✓ ✓ ✓ ✓ ✓ ✓ 
ECR-RS ✓ ✓ ✓ ✓ ✓ ✓ 
PCPW ✓ ✓ ✓ ✓ ✓ ✓ 
 
































































Variables of Interest N (%) or M (SD) 
 
N = 70 




Male:Female ratio 42:28 
Ethnicity  
White 61 (87.14%) 
Mixed 4 (5.71%) 
Asian 3 (4.29%) 
Other 2 (2.86%) 
Highest Education  
Primary (school) 9 (12.9%) 
Secondary (GCSEs) 30 (42.9%) 
Further (A levels) 22 (31.4%) 
Higher (University) 9 (12.9%) 
Relationship with Other  
Parent 43 (61.4%) 
Other relative 3 (2.9%) 
Partner 18 (25.7%) 
Friend or Other (E.g. neighbour) 6 (5.7%) 
Living Arrangements  
Parents 20 (28.6%) 
Partner 13 (18.6%) 
Alone 5 (7.1%) 
Parents and Siblings 20 (28.6%) 
Other (e.g. friends) 12 (15.7%) 
Previous Receipt of CBT  
Yes 23 (32.9%) 
No 46 (65.7%) 
Referral Source  
Early Detection / Intervention in Psychosis Service 51 (72.9%) 
Substance Misuse 5 (7.1%) 
CAMHS 1 (1.4%) 
College 1 (1.4%) 
Self-referral 4 (5.7%) 
IAPT Plus 1 (1.4%) 
Employment Support 2 (2.9%) 
Primary Care 2 (2.9%) 
Other e.g. previous engagement in research 3 (4.3%) 
 































































Variable n Percentage or M (SD) 







ARMS BLIPS 0 - 
More than one 
ARMS group 
11 15.7% 
SOFAS total 70 43.09 (9.75) 
BDI total 69 28.1 (13.3) 
SIAS total 69 42.9 (15.9) 
EQ5D health state mean 69 56.4 (23.18) 
CAARMS subscale scores N Whole sample 
M (SD) 















67 39.40 (38.20) 49 53.88 (34.78) 
Non-bizarre 
ideas severity 
70 3.07 (1.47) 63 3.41 (1.10) 
Non-bizarre 
ideas frequency 
70 3.50 (1.54) 63 3.89 (1.05) 
Non-bizarre 
ideas distress 








70 2.89 (1.37) 63 3.21 (1.02) 
 


































































68 53.13 (37.96) 61 59.23 (35.24) 
Disorganised 
speech severity 




67 2.67 (1.93) 49 3.65 (1.20) 
Disorganised 
speech distress 
67 33.94 (38.40) 49 46.41 (37.90) 
Aggression 
severity 
70 2.86 (1.51) 63 3.17 (1.23) 
Aggression 
frequency 
69 3.17 (1.61) 62 3.53 (1.26) 
Suicidality 
severity 
70 2.37 (1.53) 54 3.07 (0.93) 
Suicidality 
frequency 
67 2.27 (1.85) 51 2.98 (1.53) 
 































































Variables n M (SD) or N (%) 
BDI total 69 11.97 (13.09), 
SIAS total 69 22.83 (15.36) 
EQ-5D Dimension 
Mobility 69  
No problems  54 (78.3%) 
Problems  15 (21.7%) 
Self-care 69  
No problems  65 (94.2%) 
Problems (N, %)  4 (5.8%) 
Usual Activity 69  
No problems  53 (76.8%) 
Problems  16 (23.2%) 
Pain / discomfort 69  
No problems  43 (62.3%) 
Problems  26 (37.7%) 
Anxiety / depression 69  
No problems  40 (58.0%) 
Problems  29 (42.0%) 
Health State Mean 69 71.99 (18.87) 
ECR-RS 69  
Attachment related avoidance  20.94 (8.15) 
Attachment related anxiety  7.48 (5.45) 
 


































































Excluded/decline at referral (n=65) 
- Not want family involved (n= 13) 
- Participant declined after referral (n= 12) 
- No interest in research (n= 9) 
- Over/Under age criteria (n= 6) 
- Unable to contact once referred (n= 5) 
- Unsuitable for the study due to risk (n=4 ) 
- Antipsychotic medication (n= 3) 
- Not have family to nominate (n= 2) 
- Family declined involvement (n= 2) 
- Not help seeking (n=2) 
- Already at FEP (n=1) 
- Other reasons  (n= 6) 
Referrals (n=173) 
Initial Enquiries (n=529) Excluded/decline at initial enquiry (n=356) 
- Already at FEP (n= 82) 
- Over/Under age criteria (n= 75) 
Under 16 (n=26) 
Over 35 (n= 49) 
- Disengaged from services (n= 62) 
- Family element (n= 29) 
-Family decline (n= 1) 
-Individuals not want family involved (n= 19) 
-Individuals did not have family to nominate 
(n= 9) 
- below ARMS threshold (n=28) 
- No reason but decline (n=20) 
- In receipt of antipsychotics past / present (n= 15) 
- Not interested in research (n= 12) 
- Interpreter needed (n= 9 ) 
- No drop in functioning (n=3) 
Assessed (n=108) 
Randomised (n=70) 
Ineligible at baseline (n=38) 
- Already at FEP (n= 23) 
- Below ARMS threshold (n= 7) 
- No drop in functioning (n= 2) 
- Antipsychotic medication (n=1) 
- family member declined (n=1) 
- Not helpseeking (n=1) 
- baseline not completed (n=1) 
- possible organic impairment (n=1) 
- Decline at baseline (n=1) 
